Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT1A | P50416 | 9/20 | 0.59 |
| ▸ | CPT2 | P23786 | 4/20 | 0.59 |
| ▸ | CPT1B | Q92523 | 3/20 | 0.59 |
| ▸ | GRM5 | P41594 | 9/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1990400 | 1.00 | CPT1A (0.59) | CPT1ACPT2CPT1BGRM5 | |
| SCHEMBL4954645 | 0.97 | HCRTR1 (0.56) | CPT1ACPT2CPT1BGRM5 | |
| SCHEMBL4954639 | 0.97 | HCRTR1 (0.56) | CPT1ACPT2CPT1BGRM5 | |
| SCHEMBL17457434 | 0.94 | HCRTR1 (0.54) | CPT1ACPT2CPT1BGRM5 | |
| SCHEMBL17457435 | 0.94 | HCRTR1 (0.54) | CPT1ACPT2CPT1BGRM5 | |
| SCHEMBL16934121 | 0.92 | CPT1A (0.52) | CPT1ACPT2CPT1BGRM5 | |
| SCHEMBL16934120 | 0.92 | CPT1A (0.52) | CPT1ACPT2CPT1BGRM5 | |
| SCHEMBL19400901 | 0.90 | GRM5 (0.59) | GRM5 | |
| SCHEMBL5329277 | 0.89 | GRM5 (0.74) | GRM5 | |
| SCHEMBL3551820 | 0.89 | CPT1A (0.67) | CPT1ACPT2CPT1BGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2275105-B1 | Heterocyclic derivatives as opioid receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2016-10-05 | — | — | EP | disclosed |
| EP-2275105-B1 | Heterocyclic derivatives as opioid receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2016-10-05 | — | — | EP | disclosed |
| EP-1499313-B1 | HETEROCYCLIC DERIVATIVES AS OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-06-29 | — | — | EP | disclosed |
| EP-1499313-B1 | HETEROCYCLIC DERIVATIVES AS OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-06-29 | — | — | EP | disclosed |
| EP-2275105-A1 | Heterocyclic derivatives as opioid receptor modulators | Janssen Pharmaceutica NV (BE) | 2011-01-19 | — | — | EP | disclosed |
| US-7659402-B2 | use as pain relievers, gastrointestinal disorders; 2-Amino-3-aryl-1-[3-((hetero)aryl)piperidin-1-yl]-propan-1-one compounds | JANSSEN PHARMACEUTICA, NV (BE) | 2010-02-09 | — | — | US | disclosed |
| US-7659402-B2 | use as pain relievers, gastrointestinal disorders; 2-Amino-3-aryl-1-[3-((hetero)aryl)piperidin-1-yl]-propan-1-one compounds | JANSSEN PHARMACEUTICA, NV (BE) | 2010-02-09 | — | — | US | disclosed |
| US-7659402-B2 | use as pain relievers, gastrointestinal disorders; 2-Amino-3-aryl-1-[3-((hetero)aryl)piperidin-1-yl]-propan-1-one compounds | JANSSEN PHARMACEUTICA, NV (BE) | 2010-02-09 | — | — | US | disclosed |
| US-7202381-B2 | Compounds as opioid receptor modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2007-04-10 | — | — | US | disclosed |
| US-7202381-B2 | Compounds as opioid receptor modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2007-04-10 | — | — | US | disclosed |
| US-7202381-B2 | Compounds as opioid receptor modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2007-04-10 | — | — | US | disclosed |
| US-7041681-B2 | Compounds as opioid receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-09 | — | — | US | disclosed |
| US-20060030558-A1 | Novel compounds as opioid receptor modulators | BRESLIN HENRY J | 2006-02-09 | — | — | US | disclosed |
| US-20050187252-A1 | 2-Amino-3-(4-hydroxy-phenyl)-1-[2-(5-phenyl-oxazol-2-yl)-piperidin-1-yl]-propan-1-one; pain and gastrointestinal disorders | BRESLIN HENRY J (US) | 2005-08-25 | — | — | US | disclosed |
| US-20040010014-A1 | Novel compounds as opioid receptor modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2004-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030558-A1 | Novel compounds as opioid receptor modulators | OPRL1, OPRK1, OPRM1 | CPT1A 1124/4885CPT2 3330/4885CPT1B 1396/4885 |
| US-20050187252-A1 | 2-Amino-3-(4-hydroxy-phenyl)-1-[2-(5-phenyl-oxazol-2-yl)-piperidin-1-yl]-propan-1-one; pain and gastrointestinal disorders | OPRL1, OPRK1, OPRD1 | CPT1A 1145/4885CPT2 2960/4885CPT1B 1347/4885 |
| US-20040010014-A1 | Novel compounds as opioid receptor modulators | OPRL1, OPRK1, OPRM1 | CPT1A 1124/4885CPT2 3330/4885CPT1B 1396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.